Throckmorton Named Permanent CDER Deputy Director
This article was originally published in The Pink Sheet Daily
Executive Summary
Center for Drug Evaluation & Research Acting Deputy Director Douglas Throckmorton has been named to the position on a permanent basis, FDA announced Sept. 22
You may also be interested in...
FDA Drug Center Rotates Acting Deputy Director: Throckmorton Replaces Goldberger
Acting Center Deputy Director Goldberger will return to duties as director of Office of Drug Evaluation IV May 3, when Cardio-Renal Division Director Throckmorton will take his place. Acting Center Director Galson's letter to CDER staff indicates the center will remain without a permanent director for at least six to 12 months.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.